Manila Times Business
FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means
The agency’s letter cited manufacturing-related items and raised no safety or efficacy concerns. Werschler, a Spokane dermatologist who has served as a clinical trial investigator in dermatology and aesthetic medicine, explains how a Complete Response Letter functions and what a serotype E toxin could add to the category. SPOKANE, Wash., June 10, 2026 (GLOBE NEWSWIRE) -- AbbVie has received a Complete Response Letter from the U.S. Food and Drug Administration regarding its Biologics License Appl
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Debut Novel by Susan Price Brings 1970s Newport to Life in Summer Read
1h ago
West Red Lake Gold Announces Results of Annual General Meeting
1h ago
Fennec Announces Results of Annual Meeting
1h ago
Credit Acceptance Announces Appointment of Joe Billante as Chief Financial Officer; Jay Martin to Retire After More Than Two Decades of Service
1h ago